Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

@article{Kim2013PhaseIS,
  title={Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.},
  author={Kevin B Kim and Richard Kefford and Anna C Pavlick and Jeffrey R. Infante and Antoni Ribas and Jeffrey A. Sosman and Leslie Anne Fecher and Michael Millward and Grant Mcarthur and Patrick Hwu and Rene C. Gonzalez and Patrick Alexander Ott and Georgina V Long and Olivia S Gardner and Daniele Ouellet and Yanmei Xu and Douglas J Demarini and Ngocdiep T Le and Kiran M. Patel and Karl D. Lewis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 4},
  pages={
          482-9
        }
}
PURPOSE BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma. PATIENTS AND METHODS This was an open-label, two-stage, phase II study with two cohorts. Patients with metastatic BRAF-mutant melanoma previously treated with a BRAF inhibitor (cohort A) or treated… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 134 extracted citations

Trametinib: First Global Approval

View 8 Excerpts
Highly Influenced

MEK inhibitors beyond monotherapy: current and future development.

Current opinion in pharmacology • 2015
View 12 Excerpts
Highly Influenced

Resistance to RAF inhibitors revisited

The Journal of investigative dermatology • 2014
View 3 Excerpts
Highly Influenced

Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2015
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…